Table 2.

Statistically significant changes in hematological and serum/plasma biochemicals in patients with TDT across transfusion

Variable and control rangeBeforeAfterWeekP valueRBC units
Complete blood count 
Hb (12.0-18.0 g/dL) 9.7 ± 1.0 11.2 ± 1.0  10.6 ±0.9,  .001 17.5 ± 1.7 
HCT (37%-52%) 29.7 ± 3.1 34.0 ±3.0  32.3 ± 3.0,  .001 57.3 ± 5.9 
RBC (4200 × 109/L to 6100 × 109/L) 3700 ± 300 4200 ± 400  4000 ± 400,  .001 6100 ± 800 
MCHC (33-37 g/dL) 32.5 ± 1.3 33.0 ± 0.9  32.8 ± 1.1  .001 30.6 ± 1.8 
RETs (50 ×109/L to 100 × 109/L) 172.7 ± 256.1 187.6 ± 232.8  151.6 ± 201.7,  <.001 — 
NRBCs, per 100 WBC 76.0 ± 126.2 69.5 ± 116.1  35.2 ± 59.1,  <.001 — 
WBC (5.2 × 109/L to 12.4 × 109/L) 9.69 ± 4.20 9.76 ± 3.86 8.93 ± 4.02,  .019 0.08 ± 0.11 
Lymphocytes, ×109/L 2.56 ± 1.22 2.84 ± 1.32  2.67 ± 1.36 .024 0.02 ± 0.04 
Monocytes (0.0 × 109/L to 0.8 × 109/L) 0.74 ± 0.50 0.70 ± 0.45 0.59 ± 0.36,  .003 0.01 ± 0.01 
EOSs (0.0 × 109/L to 0.5 × 109/L) 0.18 ± 0.17 0.20 ± 0.17  0.16 ± 0.13  .022 — 
Basophils (0.0 × 109/L to 0.2 × 109/L) 0.12 ± 0.11 0.13 ± 0.10 0.11± 0.09  .021 — 
PLTs (130 × 109/L to 400 × 109/L) 422 ± 217 386 ± 195  391 ± 212  <.001 3.5 ± 3.3 
RPR 0.068 ± 0.066 0.070 ± 0.066  0.071 ± 0.065  .010 — 
Serum/plasma biochemicals 
Hepcidin (0.079-49.4 ng/mL) 29.2 ± 16.6 28.2 ± 16.4 29.8 ± 18.8  .038 — 
Thrombomodulin (2866-5318 pg/mL) 4771 ± 3730 4684 ± 3410 4409 ± 3663  .031 — 
aPTT (27-35 s) 35.9 ± 8.3 34.3 ± 8.2  35.9 ± 8.9 .019 — 
Antithrombin III activity (75%-125% of control) 90.2 ± 15.0 89.7 ± 15.5 91.4 ± 17.0,  .049 — 
ADAMTS13:Ag (370-1403 ng/mL) 1009 ± 354 1080 ± 354  1135 ± 481  .034 — 
Variable and control rangeBeforeAfterWeekP valueRBC units
Complete blood count 
Hb (12.0-18.0 g/dL) 9.7 ± 1.0 11.2 ± 1.0  10.6 ±0.9,  .001 17.5 ± 1.7 
HCT (37%-52%) 29.7 ± 3.1 34.0 ±3.0  32.3 ± 3.0,  .001 57.3 ± 5.9 
RBC (4200 × 109/L to 6100 × 109/L) 3700 ± 300 4200 ± 400  4000 ± 400,  .001 6100 ± 800 
MCHC (33-37 g/dL) 32.5 ± 1.3 33.0 ± 0.9  32.8 ± 1.1  .001 30.6 ± 1.8 
RETs (50 ×109/L to 100 × 109/L) 172.7 ± 256.1 187.6 ± 232.8  151.6 ± 201.7,  <.001 — 
NRBCs, per 100 WBC 76.0 ± 126.2 69.5 ± 116.1  35.2 ± 59.1,  <.001 — 
WBC (5.2 × 109/L to 12.4 × 109/L) 9.69 ± 4.20 9.76 ± 3.86 8.93 ± 4.02,  .019 0.08 ± 0.11 
Lymphocytes, ×109/L 2.56 ± 1.22 2.84 ± 1.32  2.67 ± 1.36 .024 0.02 ± 0.04 
Monocytes (0.0 × 109/L to 0.8 × 109/L) 0.74 ± 0.50 0.70 ± 0.45 0.59 ± 0.36,  .003 0.01 ± 0.01 
EOSs (0.0 × 109/L to 0.5 × 109/L) 0.18 ± 0.17 0.20 ± 0.17  0.16 ± 0.13  .022 — 
Basophils (0.0 × 109/L to 0.2 × 109/L) 0.12 ± 0.11 0.13 ± 0.10 0.11± 0.09  .021 — 
PLTs (130 × 109/L to 400 × 109/L) 422 ± 217 386 ± 195  391 ± 212  <.001 3.5 ± 3.3 
RPR 0.068 ± 0.066 0.070 ± 0.066  0.071 ± 0.065  .010 — 
Serum/plasma biochemicals 
Hepcidin (0.079-49.4 ng/mL) 29.2 ± 16.6 28.2 ± 16.4 29.8 ± 18.8  .038 — 
Thrombomodulin (2866-5318 pg/mL) 4771 ± 3730 4684 ± 3410 4409 ± 3663  .031 — 
aPTT (27-35 s) 35.9 ± 8.3 34.3 ± 8.2  35.9 ± 8.9 .019 — 
Antithrombin III activity (75%-125% of control) 90.2 ± 15.0 89.7 ± 15.5 91.4 ± 17.0,  .049 — 
ADAMTS13:Ag (370-1403 ng/mL) 1009 ± 354 1080 ± 354  1135 ± 481  .034 — 

Repeated measures ANOVA or Friedman (Wilcoxon) tests. For hepcidin, n = 19; for aPTT, n = 22.

ADAMTS13:Ag, ADAMTS13 antigen; aPTT, activated partial thromboplastin time; EOSs, eosinophils; HCT, hematocrit; MCHC, mean corpuscular Hb concentration; PLTs, platelets; RDW, red cell distribution width; RPR, the ratio of (RDW × 100) to (platelets).

P < .05 vs before.

P < .05 vs after.

or Create an Account

Close Modal
Close Modal